The disclosure includes novel polymorphic and pseudopolymorphic
crystalline forms of 5-azacytidine, along with methods for preparing said
forms, wherein 5-azacytidine is represented by the formula: 1
The disclosure also includes pharmaceutical compositions comprising said
forms.
